GFAP (Glial Fibrillary Acidic Protein)
Glial fibrillary acidic protein (GFAP) is released when astrocytes, the brain's support cells, become activated by injury or disease. A preventive practice tracks this emerging blood marker because elevations accompany Alzheimer's disease, brain injury, and neuroinflammation.
What It Measures
Glial fibrillary acidic protein (GFAP) is the main intermediate-filament protein of astrocytes, the brain's support cells. Plasma GFAP rises when astrocytes become reactive ("astrogliosis"), notably in response to amyloid-beta pathology, and is used as a blood marker of amyloid-associated astrocyte activation and neuroinflammation.
Optimal vs. Lab Range
Target range for optimal health and longevity based on research.
Population-based reference range from standard labs.
Why It Matters
Plasma GFAP is an early, amyloid-associated marker of Alzheimer's-type pathology: it increases in the pre-symptomatic (amyloid-positive) stage and tracks amyloid-beta more closely than tau. In prospective cohorts, higher plasma GFAP predicts progression from mild cognitive impairment to Alzheimer's dementia and is associated with cognitive decline in older adults, and recent work reports plasma GFAP can outperform CSF GFAP for detecting amyloid pathology. Combined with p-tau217 and NfL, GFAP strengthens a blood-based panel for Alzheimer's risk stratification. Because GFAP reflects astrocyte reactivity to amyloid rather than being disease-specific, it is interpreted as part of a panel and in clinical context, not as a stand-alone test.
When Low
Low/age-appropriate GFAP: little evidence of amyloid-associated astrocyte reactivity at the time of testing.
When Optimal
At or below the age-adjusted reference: reassuring; best interpreted alongside p-tau and NfL.
When High
Above the age-adjusted reference: suggests amyloid-associated astrogliosis/neuroinflammation; correlate clinically and consider confirmatory AD biomarker testing and neurology referral.
How to Optimize
GFAP reflects amyloid-linked astrocyte reactivity and neuroinflammation, so efforts focus on the shared, modifiable drivers of brain aging: a Mediterranean/MIND dietary pattern, regular aerobic and resistance exercise, good sleep, control of blood pressure, glucose and ApoB, and avoiding smoking. Where GFAP and companion markers indicate likely amyloid pathology, management is guided by neurology. This content is educational and not a substitute for medical advice.
Key Interventions & Linked Compounds
Strong (7/10)Key Interventions
Linked Compounds & Supplements
Curated from clinical literature. Individual results vary; consult a qualified clinician before changing a protocol.
Ordering Notes
Specimen
High-sensitivity plasma assay (SIMOA)
Patient prep
No fasting required. Maintain usual diet and medications unless advised.
Recommended cadence
As clinically indicated or periodically as part of a brain-health panel; compare on the same assay
Reporting unit
pg/mL
Pre-analytic notes
Standardize draw time of day, hydration, and recent exercise. Note any acute illness, supplements, or hormonal therapies on the requisition.
Available panels
Recommended Follow-Up Actions
- 1
Confirm the result is reliable
Repeat abnormal values before acting — preferably from the same lab, same time of day, and under consistent prep. Rule out acute illness, recent intense exercise, or medication effects that can shift GFAP (Glial Fibrillary Acidic Protein).
- 2
Compare against optimal, not just lab range
Use the optimal window above as the target. Lab "normal" is built from the general population and often misses early dysfunction.
- 3
Pair with related markers
Order a complementary panel covering metabolic, inflammatory, and hormonal context to interpret this marker properly.
- 4
Discuss interventions with a clinician
Use the interpretation guidance above to frame the conversation. Bring trends, not just one datapoint, to your visit.
- 5
Re-test on a defined cadence
If a change is implemented, re-measure in 8–12 weeks for fast-moving markers, or 3–6 months for slower ones, to confirm response before escalating.
Testing Information
Recommended Frequency
As clinically indicated or periodically as part of a brain-health panel; compare on the same assay
Fasting Requirement
No fasting required
Available Test Types
Quick Actions
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation
